Felipe Castillo, MD

Profile Navigation

Overview

Dr. Castillo is a board-certified, adult and addiction psychiatrist and academic faculty of the Division on Substance Use Disorders at Columbia University Medical Center (CUMC)/New York State Psychiatric Institute (NYSPI). He trained under the institutional NIDA-sponsored T32 grant, under PI Dr. Frances Levin (T32 DA007294-25). His research interests include the treatment of substance use disorders, predominantly opioid use disorder (OUD). He has worked in integrated care clinics, addressing the medical and social consequences of substance use disorders. Since completing the NIDA T32 fellowship in June of 2022, he has worked on human laboratory studies investigating the underlying mechanisms opioid use disorder and on clinical trials for SUD as a study physician at the Division’s outpatient research treatment clinic (STARS).

Academic Appointments

  • Assistant Clinical Professor of Psychiatry

Hospital Affiliations

  • NewYork-Presbyterian / Columbia University Irving Medical Center
  • NewYork-Presbyterian Hudson Valley Hospital
  • NewYork-Presbyterian Westchester

Gender

  • Male

Schedule an Appointment

Connect Patient Portal

For existing patients, login to make an appointment, view documentation or contact your care provider.

Connect Sign In

Insurance Accepted

UnitedHealthcare

  • Behavioral Health (Columbia University Employee Plan)

*Before your appointment, please contact the doctor’s office or your insurance provider to verify that your insurance is accepted. This list of insurances can change, and the insurance plans listed may not be accepted at all office locations for this provider.

Research

Selected Publications

Chen Q, Gopaldas M, Castillo F, Leckman-Westin E, Nunes EV, Levin FR, Finnerty MT. Prevalence of Opioid Use Disorder and Opioid Overdose Rates Among People With Mental Illness. Psychiatr Serv. 2024 Oct 1;75(10):953-960. doi: 10.1176/appi.ps.20230338. Epub 2024 Apr 23. PMID: 38650488.

Castillo F, Harris HM, Lerman D, Bisaga A, Nunes EV, Zhang, Z, Wall M, Comer SD. Clinical Implications of the Relationship Between Naltrexone Plasma Levels and the Subjective Effects of Heroin in Humans. Journal of Addiction Medicine:10.1097/ADM.0000000000001247, December 21, 2023. | DOI: 10.1097/ADM.0000000000001247

Luo SX, Feaster DJ, Liu, Y, Balise RR, Hu MC, Bouzoubaa L, Odom, GJ, Brandt L, Pan Y, Hser YI, VanVeldhuisen P, Castillo F, Calderon AR, Rotrosen J, Saxon, AJ, Weiss RD, Wall M, & Nunes, EV 2023. Individual-Level Risk Prediction of Return to Use During Opioid Use Disorder Treatment. JAMA psychiatry, e233596. Advance online publication. https://doi.org/10.1001/jamapsychiatry.2023.3596

Castillo F, Hu M, Liu Y, Balise R, Weiss R, Rotrosen J, Nunes E, Saxon A, Feaster D, Luo S. Risks of returning to opioid use at treatment entry and early in opioid use disorder treatment: role of non-opioid substances. Drug and Alcohol Dependence. 2023 August; :110926-. doi: 10.1016/j.drugalcdep.2023.110926.

Mahoney JJ 3rd, Winstanley EL, Castillo F, Luba R, Marton J, Alschuler DM, Liu Y, Comer SD. A pilot study investigating cognitive impairment associated with opioid overdose. Drug Alcohol Depend. 2023 Jun 1;247:109865. doi: 10.1016/j.drugalcdep.2023.109865.